CN112105598B - 用于预防或治疗肥胖或代谢综合征的化合物和包含其的药学组合物 - Google Patents

用于预防或治疗肥胖或代谢综合征的化合物和包含其的药学组合物 Download PDF

Info

Publication number
CN112105598B
CN112105598B CN201980022495.9A CN201980022495A CN112105598B CN 112105598 B CN112105598 B CN 112105598B CN 201980022495 A CN201980022495 A CN 201980022495A CN 112105598 B CN112105598 B CN 112105598B
Authority
CN
China
Prior art keywords
compound
ethanol
phenyl
present
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980022495.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN112105598A (zh
Inventor
权容兑
斯利尼瓦斯劳·甘尼皮瑟蒂
成基云
郑宜静
裵泰铉
文修兰
郑灿勋
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SNU R&DB Foundation
Original Assignee
PROTEC CO Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PROTEC CO Ltd filed Critical PROTEC CO Ltd
Publication of CN112105598A publication Critical patent/CN112105598A/zh
Application granted granted Critical
Publication of CN112105598B publication Critical patent/CN112105598B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/48—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups
    • C07C215/50—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups with amino groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/64—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C07C217/58—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms with amino groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
    • C07C209/60—Preparation of compounds containing amino groups bound to a carbon skeleton by condensation or addition reactions, e.g. Mannich reaction, addition of ammonia or amines to alkenes or to alkynes or addition of compounds containing an active hydrogen atom to Schiff's bases, quinone imines, or aziranes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/64—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms
    • C07C217/66—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms with singly-bound oxygen atoms and six-membered aromatic rings bound to the same carbon atom of the carbon chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C07C45/68—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C47/00—Compounds having —CHO groups
    • C07C47/52—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings
    • C07C47/575—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings containing ether groups, groups, groups, or groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201980022495.9A 2018-03-26 2019-03-26 用于预防或治疗肥胖或代谢综合征的化合物和包含其的药学组合物 Active CN112105598B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862648381P 2018-03-26 2018-03-26
US62/648,381 2018-03-26
PCT/KR2019/003514 WO2019190172A1 (ko) 2018-03-26 2019-03-26 신규한 화합물 및 이를 포함하는 비만 또는 대사증후군의 예방 또는 치료용 약학적 조성물

Publications (2)

Publication Number Publication Date
CN112105598A CN112105598A (zh) 2020-12-18
CN112105598B true CN112105598B (zh) 2023-06-27

Family

ID=68060316

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980022495.9A Active CN112105598B (zh) 2018-03-26 2019-03-26 用于预防或治疗肥胖或代谢综合征的化合物和包含其的药学组合物

Country Status (8)

Country Link
US (1) US12065394B2 (enExample)
EP (1) EP3778555A4 (enExample)
JP (1) JP7029213B2 (enExample)
KR (1) KR102054399B1 (enExample)
CN (1) CN112105598B (enExample)
AU (1) AU2019243133B2 (enExample)
TW (1) TWI717712B (enExample)
WO (1) WO2019190172A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11666661B2 (en) 2018-03-23 2023-06-06 The Regents Of The University Of California Methods and compounds for targeted autophagy
US12383624B2 (en) 2018-07-24 2025-08-12 Seoul National University R&Db Foundation Cargo delivery system and composition comprising the same
EP3828162B1 (en) 2018-07-24 2025-07-09 Autotac Inc. Novel p62 ligand compound, and composition for preventing, ameliorating, or treating proteinopathies comprising the same

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103930166A (zh) * 2011-08-08 2014-07-16 解向群 p62小分子化学抑制剂
WO2016200827A1 (en) * 2015-06-11 2016-12-15 University Of Pittsburgh - Of The Commonwealth System Of Higher Education P62-zz chemical inhibitor
KR20170021525A (ko) * 2015-08-18 2017-02-28 서울대학교산학협력단 p62 ZZ 도메인에 결합하는 리간드 또는 아르기닌화된 BiP에 의해 매개되는 오토파지 활성을 통한 신경변성 질환 예방 및 치료

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69227596T2 (de) 1991-10-04 1999-04-08 Taisho Pharmaceutical Co., Ltd., Tokio/Tokyo Alkoxyphenylalkylaminderivat
NO179246C (no) 1991-11-20 1996-09-04 Sankyo Co Aromatiske amino-alkoholderivater og mellomprodukter til fremstilling derav
JP3421702B2 (ja) * 1993-03-26 2003-06-30 大正製薬株式会社 シグマ受容体拮抗薬
US6462092B1 (en) 1999-09-23 2002-10-08 G.D. Searle & Co. Use of substituted N, N-disubstituted reverse aminoalcohol compounds for inhibiting cholesteryl ester transfer protein activity
WO2008011072A2 (en) 2006-07-19 2008-01-24 Osurf (Ohio State University Research Foundation) Selective androgen receptor modulators, analogs and derivatives thereof and uses thereof
KR101594168B1 (ko) * 2013-10-02 2016-02-15 서울대학교산학협력단 p62의 ZZ 영역에 의해 매개되는 자가포식 조절 방법 및 그 용도

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103930166A (zh) * 2011-08-08 2014-07-16 解向群 p62小分子化学抑制剂
WO2016200827A1 (en) * 2015-06-11 2016-12-15 University Of Pittsburgh - Of The Commonwealth System Of Higher Education P62-zz chemical inhibitor
KR20170021525A (ko) * 2015-08-18 2017-02-28 서울대학교산학협력단 p62 ZZ 도메인에 결합하는 리간드 또는 아르기닌화된 BiP에 의해 매개되는 오토파지 활성을 통한 신경변성 질환 예방 및 치료

Also Published As

Publication number Publication date
WO2019190172A1 (ko) 2019-10-03
TWI717712B (zh) 2021-02-01
US12065394B2 (en) 2024-08-20
KR102054399B1 (ko) 2019-12-10
AU2019243133A1 (en) 2020-10-08
EP3778555A1 (en) 2021-02-17
EP3778555A4 (en) 2022-03-02
AU2019243133B2 (en) 2021-03-04
US20210024454A1 (en) 2021-01-28
CN112105598A (zh) 2020-12-18
JP2021517171A (ja) 2021-07-15
TW201940461A (zh) 2019-10-16
JP7029213B2 (ja) 2022-03-03
KR20190112673A (ko) 2019-10-07

Similar Documents

Publication Publication Date Title
ES2915833T3 (es) Composiciones de isoindolina y métodos para tratar una enfermedad neurodegenerativa y una degeneración macular
AU2016391377B2 (en) 3,5-disubstituted pyrazoles useful as checkpoint kinase 1 (Chk1) inhibitors, and their preparations and applications
CN112105598B (zh) 用于预防或治疗肥胖或代谢综合征的化合物和包含其的药学组合物
US11058663B2 (en) Lipidic furan, pyrrole, and thiophene compounds for treatment of cancer, neurological disorders, and fibrotic disorders
JP7744689B2 (ja) 脂質代謝関連疾患の予防又は治療用化合物
JP4832897B2 (ja) エステル誘導体及びその医薬用途
JP7624747B2 (ja) 二置換アダマンチル誘導体、その薬学的に許容される塩、およびこれを有効成分として含む癌の増殖抑制用薬学的組成物
BR112021009921A2 (pt) composição farmacêutica que compreende inibidores de histona desacetilase 6
TW201808269A (zh) 用於治療搔癢症及／或發癢之方法
JP2020502167A (ja) ピリジン系化合物を有効成分として含有するｄｙｒｋ関連疾患の予防又は治療用薬学的組成物
JP5957452B2 (ja) 肝臓、肺の障害、糖尿病合併症および心血管疾患の処置のためのジフェニルエーテル化合物
JP2016506918A (ja) イソメテプテン異性体
JPWO2005079845A1 (ja) 片頭痛予防薬
EP4501918A1 (en) 3-phenylisoxazole derivative, and pharmaceutical composition for preventing or treating eye disease, containing same as active ingredient
US20190127320A1 (en) Kcnq2-5 channel activator
WO2018015862A1 (en) 1-methylnicotinamide salts for use in raising the blood levels of adiponectin
US9580399B2 (en) Geranyl flavonoid derivative with improved water solubility, a method for preparing the same, and a method for treating cancer using the same
KR20250083163A (ko) 신규 화합물 및 이를 포함하는 안질환 예방 또는 치료용 조성물

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20240122

Address after: Seoul, South Kerean

Patentee after: SNU R&DB FOUNDATION

Country or region after: Republic of Korea

Address before: Seoul, South Kerean

Patentee before: Protec Co.,Ltd.

Country or region before: Republic of Korea

TR01 Transfer of patent right